A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer. Our scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (“XPO1”). These compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of diseases with high unmet medical need. Our lead asset, XPOVIO® (selinexor), was the first oral XPO1 inhibitor to receive marketing approval, receiving its initial U.S. approval from the U.S. Food and Drug Administration (“FDA”) in July 2019, and is currently approved and marketed in the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 146M | 146M | 145M | 146M | 157M | 210M |
| Net Income | -196M | -196M | -76M | -143M | -165M | -124M |
| EPS | $-17.93 | $-17.93 | $-14.00 | $-18.75 | $-30.30 | $-24.75 |
| Free Cash Flow | -75M | -75M | -128M | -93M | -150M | -107M |
| ROIC | -66.1% | -83.7% | -72.6% | -53.9% | -31.4% | -25.4% |
| Gross Margin | 95.9% | 95.9% | 95.9% | 96.6% | 96.7% | 98.4% |
| Debt/Equity | 0.00 | -0.47 | -0.51 | -0.00 | -10.21 | -2.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -91M | -91M | -119M | -130M | -142M | -98M |
| Operating Margin | -62.1% | -62.1% | -82.2% | -88.7% | -90.5% | -46.8% |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 11M | 11M | 18M | 8M | 5M | 5M |
Karyopharm Therapeutics Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 96.7%.
Karyopharm Therapeutics Inc. (KPTI) has a 5-year average return on invested capital (ROIC) of -53.4%. This is below average and may indicate limited pricing power.
Karyopharm Therapeutics Inc. (KPTI) has a market capitalization of $92M. It is classified as a small-cap stock.
Karyopharm Therapeutics Inc. (KPTI) does not currently pay a regular dividend.
Karyopharm Therapeutics Inc. (KPTI) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Karyopharm Therapeutics Inc. (KPTI) reported annual revenue of $146 million in its most recent fiscal year, based on SEC EDGAR filings.
Karyopharm Therapeutics Inc. (KPTI) has a net profit margin of -134.2%. The company is currently unprofitable.
Karyopharm Therapeutics Inc. (KPTI) generated $-75 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Karyopharm Therapeutics Inc. (KPTI) reported earnings per share (EPS) of $-17.93 in its most recent fiscal year.
Karyopharm Therapeutics Inc. (KPTI) has a 5-year average gross margin of 96.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for Karyopharm Therapeutics Inc. (KPTI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Karyopharm Therapeutics Inc. (KPTI) has a book value per share of $-26.79, based on its most recent annual SEC filing.